CANNABIS: A Promising Option for the Opioid Crisis

October 2016

National Cannabis Industry Association
TheCannabisIndustry.org
Special thanks to the following individuals whose contributions of time, insight, and materials made this report possible:

Marcus Bachhuber
Albert Einstein College of Medicine

W. David Bradford
University of Georgia

Devin Butts

Karen Corsi
University of Colorado

Kelly Dunn
Johns Hopkins
University

June Kim
Columbia University

Julie Netherland
Drug Policy Alliance

Rosalie Pacula
The Rand Corporation

Amanda Reiman
Drug Policy Alliance

Donna Schwier

Jack Stiegelman

Dustin Sulak
Integr8 Health

Kyle Turley

Melissa Wilcox
Americans for Safe Access

ADVOCACY. EDUCATION. COMMUNITY.

The National Cannabis Industry Association is the only national trade association advancing the interests of the legitimate and responsible cannabis industry. Our industry supports tens of thousands of jobs, tens of millions in tax revenue, and billions in economic activity in the United States. NCIA is leading the unified and coordinated campaign to ensure this emerging sector is treated fairly under federal law. For more information on NCIA, please visit TheCannabisIndustry.org.
WHAT IS THE OPIOID CRISIS?

The Centers for Disease Control and Prevention have declared that the United States is in the middle of an “opioid overdose epidemic.” In 2014, opioids, which are drugs used to decrease pain and include both prescription pain relievers like oxycodone as well street drugs like heroin, killed more than 28,000 people, a larger number than any previous year.¹ Now more people die from heroin and other opioid overdoses than from car crashes.

The crisis is an equal-opportunity killer – opioid overdoses are going up among all races, especially among whites and Native Americans.²

“It wasn’t considered a crisis until it started impacting middle-class white people,” says Amanda Reiman, manager of marijuana law and policy at the Drug Policy Alliance. “When you start to see it happening in places that are not aligning with people’s expectations, folks start to notice.”

Skyrocketing use of prescription pain relievers, thanks to looser prescription guidelines and aggressive pharmaceutical marketing campaigns, has helped fuel the epidemic. Since 1999, prescription opioid sales have nearly quadrupled nationwide, despite the fact that there’s little data supporting such drugs’ long-term use and there’s been no major change in the amount of pain patients are reporting.³

Currently the health care, productivity and criminal justice costs of prescription opioid abuse nationwide are estimated to top $78 billion annually.4

Addressing the crisis has become a bipartisan political imperative, with the Obama administration earlier this year promising $1.1 billion in new funding to tackle the problem and signing the Comprehensive Addiction and Recovery Act (CARA), which expands access to treatment and recovery.

But CARA received less than half the funding that its backers requested, and the law focuses on post-addiction treatments. There is little emphasis on strategies that could help reduce opioid use and addiction in the first place.5

While opioid addiction medications such as methadone, buprenorphine, and naltrexone have proven to be successful treatments for many users, the drugs can come with debilitating side effects, and they can be costly and difficult to obtain from treatment centers.

Of the 2.5 million Americans who abused opioids in 2012, less than a million received medication-assisted treatments that year.6

2 Medical Cannabis Access for Pain Treatment: A Viable Strategy to Address the Opioid Crisis.” Americans for Safe Access, 2016.
CAN CANNABIS HELP REDUCE PRESCRIPTION OPIOID USE?

Medical cannabis has long been seen as a potential alternative to prescription painkillers, since its analgesic, or pain-relieving, effects have been well documented.

In 2010, the Center for Medicinal Cannabis Research at the University of California concluded, after a decade of clinical studies on the matter, that “we now have reasonable evidence that cannabis is a promising treatment in selected pain syndromes caused by injury or diseases of the nervous system, and possibly for painful muscle spasticity due to multiple sclerosis.”

A 2015 review of 38 randomized controlled trials evaluating cannabinoids in pain management found that in 71 percent of the studies, “cannabinoids had empirically demonstrable and statistically significant pain-relieving effects.”

It’s also scientifically established that cannabis is far safer than any opioid, prescription or otherwise; while heroin has a lethal dose that is just five times its effective dose and codeine can be lethal at 20 times its effective dose, no one knows the lethal toxicity of cannabis, because there’s never been a documented case of a cannabis overdose death.

What’s more, scientists have found that when used in combination with prescription painkillers, cannabis can increase the pain-relieving properties of opioids and lower negative side effects.

“There is a lot of data suggesting if you pair high-potency cannabinoids with opioids, you get an enhanced effect,” says Kelly Dunn, a professor of behavioral pharmacology at Johns Hopkins University. “So you don’t need as many opioids to reduce pain.” Reducing opioid use could lower the potential for abuse.

It’s why doctors like Dustin Sulak, an osteopathic physician in Maine who specializes in medical cannabis, have found cannabis lowers their patients’ dependence on opioids.

---

7 Grant, Igor et al. “Report to the legislature and governor of the state of California presenting findings pursuant to SB847 which created the CMCR and provided state funding.” University of California, 2010.
"Usually if a patient is taking opioids, you expect them to come back and ask for more, because their effectiveness diminishes over time," he says. "But we saw patients using cannabis decreasing and stopping their use of opioids without even being asked to. None of us had seen anything like it in any area of medicine."

A survey of 542 of his patients using cannabis alongside opioids found that 39 percent reduced their opioid dosage and another 39 percent stopped using opioids altogether.  

That could be why a 2016 analysis of prescription drugs sold under Medicare Part D from 2010 to 2013 found that drug sales were markedly lower in the 17 states that then had medical cannabis laws, particularly when it came to painkillers.

On average, the typical physician in a medical cannabis state prescribed 1,826 fewer pain pill doses each year.

```
<table>
<thead>
<tr>
<th>Condition</th>
<th>Savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>1,826</td>
</tr>
<tr>
<td>Anxiety</td>
<td>582</td>
</tr>
<tr>
<td>Nausea</td>
<td>541</td>
</tr>
<tr>
<td>Psychosis</td>
<td>519</td>
</tr>
<tr>
<td>Seizures</td>
<td>486</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>362</td>
</tr>
<tr>
<td>Depression</td>
<td>265</td>
</tr>
<tr>
<td>Spasticity</td>
<td>32</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>35 more</td>
</tr>
</tbody>
</table>
```

"The results were very robust, particularly for pain medications," says W. David Bradford, University of Georgia professor and co-author of the study. "This is one more piece of evidence that people are treating marijuana like medicine."

All in all, the study’s authors concluded that state medical cannabis programs were responsible for $165.2 million in Medicare prescription savings in 2013.  

---

On top of that, according to a draft follow-up paper looking at Medicaid drug sales, medical cannabis was responsible for $178.5 million in 2014 Medicaid prescription savings.13 Declining opioid sales could be one of the main reasons why major pharmaceutical companies are fighting cannabis reforms.

Purdue Pharma, the maker of OxyContin, and Abbot Laboratories, the company behind Vicodin, have been among the largest donors to the anti-cannabis organization Partnership for Drug-Free Kids, and various opioid manufacturers have also donated to a similar operation, the Anti-Drug Coalition of America.14

In August 2016, the opposition campaign to Arizona’s ballot initiative seeking to tax and regulate cannabis received a $500,000 donation from Insys Therapeutics, Inc., which is developing a synthetic cannabis product and manufactures the powerful opioid painkiller Fentanyl, which is estimated to have 80 times the potency of morphine.15

CAN CANNABIS HELP REDUCE OPIOID ABUSE AND OVERDOSES?

Evidence is mounting that cannabis can also help reduce opioid abuse and addiction, since users of opioids, both legal and illegal, view cannabis as a safer alternative.

A 2015 study of 653 illicit injection opioid users in Los Angeles and San Francisco found that those who consumed cannabis used significantly less opioids in a 30-day period than those who didn’t.16

A 2016 report from Castlight Health, a San Francisco health care information company, found that in states with medical cannabis laws, only 2.8 percent of those with an opioid prescription qualified as abusers, compared to 5.4 percent of opioid users in states without medical cannabis laws.17

A 2015 working paper from the RAND Bing Center for Health Economics found that states with medical cannabis dispensaries reported a 28 to 35 percent reduction in opioid

addiction treatment admissions, plus a 16 to 31 percent reduction in opioid overdose deaths.  

The most striking data, however, comes from a 2014 study of lethal opioid overdoses between 1999 and 2010. That survey found that the 13 states with medical cannabis laws during that period had 25 percent fewer opioid deaths than other states. What’s more, the effect of medical cannabis appeared to strengthen over time – overdose death reductions grew from roughly 20 percent the first year after medical marijuana implementation to nearly 34 percent five years after implementation.  

“We think that this points towards cause and effect, although you can never say it with 100-percent certainty,” says Marcus Bachhuber, lead author of the study.

Bachhuber’s findings were recently bolstered by an analysis of federal crash data that found that states with medical cannabis laws have also experienced a reduction in opioid-related fatal car accidents.  

Cannabis might not just help reduce opioid addiction; it might also prove to be a useful treatment for it, since cannabis is often used to treat conditions that are common symptoms of opioid withdrawal, such as nausea, anxiety, and muscle pain.

---

A 2013 Thomas Jefferson University study of 91 patients receiving methadone treatments discovered that those patients who also used cannabis experienced the fewest withdrawal symptoms.\textsuperscript{21}

A 2009 study of rats that were taught to self-administer heroin found that once the rats were taken off the drug for two weeks, animals that were treated with cannabidiol were markedly less likely to seek out heroin again.\textsuperscript{22}

Opioid addiction treatment, in fact, could become a new opportunity for the growing medical cannabis market.

“Treatment for opioid addiction is an industry in itself,” says Reiman at the Drug Policy Alliance. “If we as an industry can embrace this kind of natural, low-cost treatment for people who are looking for a way off of opioids, that is a whole part of the industry we haven’t really seen yet.”

\textbf{WHY IS CANNABIS BEING BLAMED FOR THE OPIOID CRISIS?}

Anti-marijuana advocates often use the opioid crisis as an argument against legalization.

In Vermont, concerns about opioids helped derail the state legislature’s efforts to create a legal, regulated adult-use cannabis program there in early 2016.

“The shadow of the heroin epidemic is something that people think about when they think about the legalization, and they ask themselves, ‘Are we sending the right message about legalization?’” Shap Smith, Vermont’s speaker of the House, told the New York Times in April. “I think in the public’s mind, it’s making passage of this bill more difficult.”\textsuperscript{23}

In an op-ed announcing their opposition to the cannabis legalization measure on Massachusetts’ 2016 ballot, Governor Charlie Baker, Attorney General Maura Healey and Boston Mayor Martin Walsh explicitly noted their state’s opioid epidemic as a reason for their objections.

“For the past year, our teams have worked tirelessly, together and with our partners across Massachusetts, to combat the heroin and prescription-drug epidemic that is ravaging our

state...We should not be expanding access to a drug that will further drain our health and safety resources.²⁴

But the concept of marijuana as a "gateway drug," leading to increased use of opioids or other narcotics, has been largely debunked.

A 1999 report from the Institute of Medicine, for example, noted "marijuana does not appear to be a gateway drug to the extent that it is the cause or even that it is the most significant predictor of serious drug abuse."²⁵

A 2010 Rand Drug Policy Research Center working paper on cannabis coffee shops in the Netherlands concluded that legalized cannabis appeared to create a "weakened gateway" to other drugs, since Dutch cannabis users were less likely to have tried cocaine and amphetamines than other European countries.²⁶

One reason for this phenomenon could be that Dutch cannabis users had less contact with drug dealers and addicts; another reason could be that it’s not cannabis that functions as a gateway to hard drugs, but cannabis prohibition. Thanks to the illegality of cannabis, some people might turn to opioids and other hard drugs because traces of these substances aren’t as likely to show up on mandatory drug tests.

In comparing the two, it’s also important to understand that the biological mechanisms behind the effects of cannabis and opioids are very different.

Cannabinoids and other chemical components of cannabis function by targeting cannabinoid receptors throughout the body that are involved in regulating physiological processes such as appetite, pain perception, mood, and memory.

Opioids, however, reduce pain by targeting opioid receptors, a process that rapidly increases opioid tolerance levels and can become highly addictive.²⁷

WHAT NEEDS TO BE DONE?

Cannabis could become a powerful tool in the fight against the opioid crisis, but much work on the matter remains. Policymakers tackling the crisis should take steps on several levels.

WORK FOR FEDERAL CANNABIS REFORMS

- **Deschedule marijuana.** Marijuana should be removed from the Controlled Substances Act, so that researchers will be able to thoroughly conduct the necessary research into the potential of cannabis as an analgesic, opioid replacement, and addiction treatment. Descheduling marijuana, which would allow states to set and enforce their cannabis policies without federal interference, would also protect patient access to cannabis for pain management and other treatments.

- **Allow V.A. doctors to discuss medical cannabis.** Veterans Affairs physicians are currently forbidden to discuss medical marijuana with their patients, even in states where medical cannabis access is legal. Veterans frequently struggle with chronic pain, injuries, PTSD and other psychological disorders, and heavy prescription opioid use or abuse — all conditions for which medical marijuana can be beneficial. V.A. doctors should be able to converse candidly with their patients about all their treatment options.

- **Allow cannabis banking to create safer conditions for access.** Due to federal regulation of financial institutions, most cannabis providers are denied access to basic banking services, forcing them to operate entirely in cash. Banks should be allowed to serve state-compliant cannabis businesses in order to alleviate the significant public safety challenges an all-cash business creates for providers, their patients, and the regulators overseeing them.

SUPPORT STATE-LEVEL EFFORTS TO OPEN UP AND REGULATE ACCESS TO CANNABIS

Marijuana policy reform is currently happening primarily at the state level, through both ballot initiatives and legislative action. There are many legitimate and beneficial reasons that states choose to create regulated programs for cannabis access.

For policy-makers focused on addressing and reducing the opioid crisis in their states, there is now powerful evidence that they should support increased cannabis access for that reason.
INCLUDE CHRONIC PAIN AS A QUALIFYING CONDITION IN ALL STATE MEDICAL CANNABIS LAWS

Lawmakers such as Senator Elizabeth Warren\textsuperscript{28} and Congressman Earl Blumenauer\textsuperscript{29} support using medical cannabis as a pain treatment to combat the opioid epidemic.

In June 2016, Vermont Governor Pat Shumlin added chronic pain to his state's list of qualifying conditions, noting, "At a time when opioid addiction is ravaging our state and drug companies continue to urge our doctors to pass out painkillers like candy, we need to find a more practical solution to pain management."\textsuperscript{30}

But of the 26 full medical cannabis programs nationwide, only three-quarters currently include chronic pain as a qualifying condition, and several place restrictions on what sort of chronic pain can qualify.\textsuperscript{31}

REJECT FALSE "GATEWAY THEORY" ANTI-MARIJUANA RHETORIC

Those who oppose increasing legal cannabis access because of the opioid epidemic are not just advancing a false theory; they're standing in the way of a highly promising alternative for people struggling with opioid use and abuse.

Scientific research, as well as personal stories of those who've used cannabis to decrease or stop opioid use, rejects the "gateway theory," and policy-makers should do so as well.

LOWER THE COST AND EXPAND ACCESS TO CANNABIS FOR THOSE WHO NEED IT

Insurance companies need to recognize cannabis as a promising and safe alternative to opioid painkillers, and addiction treatment programs should include cannabis in their arsenal of substance abuse treatment options.

Doing so is not just a social good; it could equal millions in health care cost savings.

For questions or comments about this report, please contact NCIA at info@thecannabisindustry.org or (888) 683-5650.